Drug Trial Radar · NCT06347003
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
446
Actual
Start
Jul 22, 2024
Primary completion
Jun 12, 2026
Study completion Aug 25, 2026
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Conditions
- Severe Hypertriglyceridemia
Interventions
Plozasiran InjectionDrug
ARO-APOC3 Injection
PlaceboDrug
sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to PlaceboTime frame: Baseline, Month 12
Locations
196 sites in 17 countries. Site status is shown where the registry gives one.
Research Center 1
Garden Grove, California
Research Center 2
Lake Forest, California
Research Center 3
Montclair, California
Research Center 4
Panorama City, California
Research Center 5
Redding, California
Research Center 6
Colorado Springs, Colorado
Research Center 7
Hialeah, Florida
Research Center 8
Lake City, Florida
Research Center 9
Miami Lakes, Florida
Research Center 10
Mt. Dora, Florida
Research Center 11
Orlando, Florida
Research Center 12
Pensacola, Florida
Research Center 13
Tamarac, Florida
Research Center 14
Tampa, Florida
Research Center 15
Macon, Georgia
Research Center 16
Savannah, Georgia
Research Center 17
Park Ridge, Illinois
Research Center 18
Eunice, Louisiana
Research Center 19
Baltimore, Maryland
Research Center 20
Flint, Michigan
Research Center 21
Minneapolis, Minnesota
Research Center 22
Olive Branch, Mississippi
Research Center 23
Jefferson City, Missouri
Research Center 24
St Louis, Missouri
Research Center 26
Omaha, Nebraska
Research Center 25
Omaha, Nebraska
Research Center 27
Las Vegas, Nevada
Research Center 29
Long Island City, New York
Research Center 30
New York, New York
Research Center 31
Rochester, New York
Research Center 28
The Bronx, New York
Research Center 32
Vestal, New York
Research Center 33
Morehead City, North Carolina
Research Center 34
Winston-Salem, North Carolina
Research Center 35
Cincinnati, Ohio
Research Center 36
Columbus, Ohio
Research Center 37
Norman, Oklahoma
Research Center 38
Oklahoma City, Oklahoma
Research Center 39
Powell, Tennessee
Research Center 40
El Paso, Texas
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.